Capricor Therapeutics (CAPR) Common Equity (2016 - 2025)
Historic Common Equity for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to $83.9 million.
- Capricor Therapeutics' Common Equity rose 2285.55% to $83.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.9 million, marking a year-over-year increase of 2285.55%. This contributed to the annual value of $145.5 million for FY2024, which is 54359.69% up from last year.
- According to the latest figures from Q3 2025, Capricor Therapeutics' Common Equity is $83.9 million, which was up 2285.55% from $105.0 million recorded in Q2 2025.
- Over the past 5 years, Capricor Therapeutics' Common Equity peaked at $145.5 million during Q4 2024, and registered a low of -$1.8 million during Q3 2023.
- Its 5-year average for Common Equity is $42.0 million, with a median of $24.6 million in 2022.
- As far as peak fluctuations go, Capricor Therapeutics' Common Equity tumbled by 11158.82% in 2023, and later skyrocketed by 391868.54% in 2024.
- Capricor Therapeutics' Common Equity (Quarter) stood at $31.4 million in 2021, then plummeted by 62.43% to $11.8 million in 2022, then skyrocketed by 91.76% to $22.6 million in 2023, then soared by 543.6% to $145.5 million in 2024, then plummeted by 42.34% to $83.9 million in 2025.
- Its last three reported values are $83.9 million in Q3 2025, $105.0 million for Q2 2025, and $127.6 million during Q1 2025.